{"title":"Salix加入税收倒置浪潮，同意与Cosmo制药公司的爱尔兰子公司合并","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i8.2054","DOIUrl":null,"url":null,"abstract":"Continuing the tax inversion trend among US-based companies in the life sciences sector, Salix Pharmaceuticals has agreed to buy the Ireland-domiciled subsidiary of Italian speciality pharmaceutical company Cosmo Pharmaceuticals in an all-stock deal valued at approximately US$2.7 B. The deal will lower Salix’s effective long-term tax rate from the high 30% range at present to the low 20% range and will give the company ownership of Cosmo’s US patents for three gastrointestinal products, including Uceris® (budesonide) for ulcerative colitis.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2014i8.2054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Continuing the tax inversion trend among US-based companies in the life sciences sector, Salix Pharmaceuticals has agreed to buy the Ireland-domiciled subsidiary of Italian speciality pharmaceutical company Cosmo Pharmaceuticals in an all-stock deal valued at approximately US$2.7 B. The deal will lower Salix’s effective long-term tax rate from the high 30% range at present to the low 20% range and will give the company ownership of Cosmo’s US patents for three gastrointestinal products, including Uceris® (budesonide) for ulcerative colitis.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2014i8.2054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2014i8.2054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Salix Joins the Tax Inversion Wave by Agreeing to Merge with Cosmo Pharmaceuticals’ Irish Unit
Continuing the tax inversion trend among US-based companies in the life sciences sector, Salix Pharmaceuticals has agreed to buy the Ireland-domiciled subsidiary of Italian speciality pharmaceutical company Cosmo Pharmaceuticals in an all-stock deal valued at approximately US$2.7 B. The deal will lower Salix’s effective long-term tax rate from the high 30% range at present to the low 20% range and will give the company ownership of Cosmo’s US patents for three gastrointestinal products, including Uceris® (budesonide) for ulcerative colitis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
